FOLD - AMICUS THERAPEUTICS, INC.
IEX Last Trade
9.78
-1.110 -11.350%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$10.89
-1.11
-10.19%
Fundamental analysis
7%
Profitability
0%
Dept financing
22%
Liquidity
49%
Performance
0%
Performance
5 Days
-0.10%
1 Month
0.72%
3 Months
-10.02%
6 Months
-0.81%
1 Year
-28.01%
2 Year
-16.11%
Key data
Stock price
$9.78
DAY RANGE
$9.79 - $10.89
52 WEEK RANGE
$9.45 - $14.57
52 WEEK CHANGE
-$32.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Bradley L. Campbell
Region: US
Website: amicusrx.com
Employees: 480
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amicusrx.com
Employees: 480
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Amicus Therapeutics, Inc. focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases.
Recent news